Genzyme Corp.’s decision to deepen its 2012 alliance with Alnylam Pharmaceuticals Inc. potentially sets its rare disease division on a path to sustainable growth and puts its formidable emerging markets engine in the service of Alnylam’s pipeline.
Alnylam gets a partner that can help build the value of its RNAi candidates while allowing it to retain product...